glp-1 stimulation receptor assay: drug discovery in the metabolic field Recent updates on GLP-1 agonists:

Oncology includes PD-1 and other cancer treatments

24 h post seeding, 1.8 g of luciferase reporter vector pGL4.37 ( luc2P /ARE/Hygro) (Promega Corp., Fitchburg, WI, USA), 0.2 g of Renilla luciferase control vector (pRL-SV40) (Promega Corp., Fitchburg, WI, USA) were used for the transfection of a single well with the Transporter 5 Transfection Reagent (PolyScience, Niles, IL, USA)

Int J Cancer 127:18131822 Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

This is a fundamentally different strategy

Catelli JM, Giakas WJ, Sved AF